MedTrace Logo

Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse

NCT00753792 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2011-06-02

No results posted yet for this study

Summary

This is a phase IV, multicenter, randomized, double blind clinical trial. The investigators will study 48 patients with remitting relapsing multiple sclerosis (MS) experiencing moderate or severe attack receiving immunomodulatory therapy or not. Patients will be randomly assigned to one of the two groups.

Conditions

Interventions

DRUG

methylprednisolone

methylprednisolone 1.000 mg/day intravenous administration during three days

DRUG

methylprednisolone

methylprednisolone 1.250 mg/day orally administered during three days

DRUG

Placebo

Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)

Sponsors & Collaborators

  • Germans Trias i Pujol Hospital

    lead OTHER

Principal Investigators

  • Cristina Ramo, MD · Germans Trias i Pujol Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-11-30
Completion
2011-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00753792 on ClinicalTrials.gov